KLONOPIN RAPIDLY DISINTEGRATING Drug Patent Profile

Which patents cover Klonopin Rapidly Disintegrating, and what generic alternatives are available?

Klonopin Rapidly Disintegrating is a drug marketed by Roche and is included in one NDA.

The generic ingredient in KLONOPIN RAPIDLY DISINTEGRATING is clonazepam. There are ten drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Klonopin Rapidly Disintegrating

A generic version of KLONOPIN RAPIDLY DISINTEGRATING was approved as clonazepam by TEVA on September 10^th, 1996.

Summary for KLONOPIN RAPIDLY DISINTEGRATING

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,858
DailyMed Link:	KLONOPIN RAPIDLY DISINTEGRATING at DailyMed

US Patents and Regulatory Information for KLONOPIN RAPIDLY DISINTEGRATING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-001	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-004	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-002	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-003	Dec 23, 1997		DISCN	Yes	No
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-005	Dec 23, 1997		DISCN	Yes	No

Expired US Patents for KLONOPIN RAPIDLY DISINTEGRATING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-002	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-005	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-001	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-005	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-003	Dec 23, 1997
Roche	KLONOPIN RAPIDLY DISINTEGRATING	clonazepam	TABLET, ORALLY DISINTEGRATING;ORAL	020813-004	Dec 23, 1997

International Patents for KLONOPIN RAPIDLY DISINTEGRATING

See the table below for patents covering KLONOPIN RAPIDLY DISINTEGRATING around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2882577
Australia	513845
Belgium	859291
Canada	1083042	FORME PHARMACEUTIQUES POUR ADMINISTRATION PAR VOIE ORALE (PHARMACEUTICAL DOSAGE FORMS FOR ORAL ADMINISTRATION)
Canada	1097233	EMBALLAGES (PACKAGES)
Switzerland	633717	Moulded carrier for chemicals and/or pharmaceuticals

Last updated: July 4, 2026

ONOPIN RAPIDLY DISINTEGRATING (clonazepam) market dynamics and financial trajectory

KLONOPIN RAPIDLY DISINTEGRATING is a clonazepam oral-dosage product positioned in US and select international markets for acute seizure and anxiety-related indications, but its financial trajectory is structurally constrained by (1) widespread generics of clonazepam, (2) tight payer utilization management for benzodiazepines, and (3) ongoing substitution and channel-down pricing pressure. Net sales trend is typically dominated by (a) brand share erosion versus generics, (b) ongoing pharmacy benefit manager (PBM) formulary placement and rebate dynamics, and (c) unit volatility driven by label mix and prescriber behavior in epilepsy and anxiety.

How do generic clonazepam dynamics shape the KLONOPIN RAPIDLY DISINTEGRATING sales trajectory?

Short answer: Brand revenue is mechanically pressured by generic substitution, aggressive price competition, and category-level utilization controls for benzodiazepines.

What drives substitution pressure for clonazepam RDTs?

Clonazepam is a mature small-molecule benzodiazepine with long-standing generic availability across multiple oral dosage formats. Rapidly disintegrating tablet (RDT) brands compete on convenience rather than active pharmaceutical ingredient uniqueness. That creates a predictable spend pattern:

• Pharmacy-level substitution: When payers and pharmacy networks are configured for generics, RDT brands lose non-medical-switch demand.
• Therapeutic-class scrutiny: Benzodiazepines face heightened payer and health-system controls, which shifts demand to lower-cost products unless the RDT format is explicitly required.
• Formulary tiering: Brand placement in preference tiers is typically eroded over time unless rebate economics preserve access.

How does channel pricing affect brand net sales when generics dominate?

For older benzodiazepam brands, net sales tend to compress due to:

• Rebate pressure: Higher rebates are required to maintain formulary access as generic offers deepen.
• Wholesale and retail inventory cycles: RDT-specific demand can cause localized inventory mismatches, which in turn affects sell-through and returns.
• Package-size competition: Generic packs often match clinically common dosing patterns, limiting differentiation.

What is the payer and PBM impact on KLONOPIN RAPIDLY DISINTEGRATING demand?

Short answer: PBM utilization management is the primary lever for demand stabilization, with steeper headwinds in periods of generic price resets.

Which contracting structures most influence clonazepam brand performance?

Brand resilience in mature benzodiazepines typically depends on:

• Preferred brand vs. nonpreferred brand positioning: If the RDT is not preferred relative to generics, net sales remain exposed.
• Copay dynamics: Managed care can increase copays for non-preferred brands, shifting demand to generics.
• Quantity limits and prior authorization: Even without strict limits, these tools can reduce monthly fills for anxiety-related use.

Does indication mix change financial trajectory?

Yes. Epilepsy-related use can be stickier for patients and prescribers, but anxiety-related use is more elastic and more sensitive to formulary access. Brand share is usually more durable in seizure control populations where switching is more clinically constrained.

How does competition from generic clonazepam and alternative formulations change market share?

Short answer: The competitive set is not only “generic clonazepam tablets,” but also liquid and orally disintegrating alternatives and store-brand equivalents where available.

What substitution pathways reduce KLONOPIN RDT differentiation?

• Direct generic switching: Equivalent-strength clonazepam tablets typically cover most use cases.
• Non-RDT formulation substitution: If prescribers do not require disintegration characteristics, demand is replaceable.
• Therapeutic overlap with other benzos: While clonazepam is not directly interchangeable across all clinical decisions, category-wide benzo prescribing patterns can shift within physician panels.

What does a typical share erosion curve look like in this category?

In mature, generic-dominated benzodiazepines, brand share commonly declines in steps:

1. Early generic entrance and first-year share loss.
2. Periodic deeper price competition as additional generic manufacturers scale.
3. Ongoing rebate and formulary adjustments driven by PBM contracting.

What regulatory and labeling factors influence commercial uptake for KLONOPIN RAPIDLY DISINTEGRATING?

Short answer: Label scope sets the maximum addressable use. Practical commercial uptake then hinges on safety surveillance norms and payer risk controls.

How do benzodiazepine safety considerations affect contracting?

Commercial access is shaped by:

• Dose and duration monitoring expectations
• Concomitant substance risk management (eg, opioids)
• Prescriber behavior under stewardship programs

Those factors tend to reduce new-start volume unless the brand is demonstrably needed in a patient-specific context.

When do KLONOPIN RAPIDLY DISINTEGRATING exclusivity or patent milestones meaningfully matter for revenue?

Short answer: For a clonazepam brand, near-to-midterm revenue depends less on brand exclusivity and more on generic saturation and channel economics.

What to expect from the exclusivity/patent timeline in mature clonazepam brands?

With multiple generic entrants historically, brand protection is usually limited to:

• formulation-level exclusivities (if any remain)
• specific packaging or secondary patents that are often overcome in practice
• regulatory data exclusivity outcomes that do not prevent generic entry at scale

The practical effect is that “milestone dates” rarely reverse an established generic substitution baseline.

How does distribution and inventory management affect quarter-by-quarter financial performance?

Short answer: Unit demand volatility for disintegration-focused SKUs is more pronounced, causing quarter-to-quarter swings even when broader clonazepam demand is stable.

What operational factors move sales in RDT products?

• Inventory correction cycles: returns and channel adjustments after generic price moves
• Regional contracting differences: wholesalers pass through PBM-driven mix changes at different speeds
• Seasonality in anxiety-related use: anxiety-driven prescribing can show short-term variability

What financial trajectory should be expected versus other benzodiazepine brands?

Short answer: KLONOPIN RDT is likely to follow a “down-and-stabilize” pattern typical of mature branded benzodiazepines: falling share after generic entry, then stabilization at a lower revenue base tied to patient-level continuity and formulary carve-outs.

Comparative pattern across legacy benzodiazepine brands

In similar categories, branded performance usually shows:

• Declining gross-to-net margins if rebates rise faster than sales volume
• Higher marketing and access spend to defend remaining share
• Lower net revenue elasticity once the product becomes non-preferred

What commercial risks exist for KLONOPIN RAPIDLY DISINTEGRATING?

Short answer: The dominant risks are formula replacement by generics, payer tier changes, and patient switching costs that typically work against brand hold.

Key downside vectors

• Formulary re-tiering by PBMs: moving the RDT from preferred to nonpreferred
• Generic price pressure leading to lower rebate effectiveness: brand net may fall even if list prices remain
• Switching behavior: rapid substitution where prescribers and patients do not require RDT-specific administration
• Manufacturing and supply continuity risks: RDT SKUs can be sensitive to batch disruptions, which can worsen share loss

How does KLONOPIN RAPIDLY DISINTEGRATING fit into epilepsy and anxiety market forecasts?

Short answer: It competes within established epilepsy and anxiety demand pools, but its brand share is the variable, not the overall category incidence.

Epilepsy pool

Epilepsy prescription continuity tends to slow switching, which can preserve a floor for branded demand, even in generic-heavy markets.

Anxiety pool

Anxiety-related prescribing is more sensitive to:

• stewardship initiatives
• payer controls
• prescriber risk-benefit thresholds

This creates a larger near-term demand variance.

What are the most likely outcomes under plausible payer and pricing scenarios?

Short answer: Revenue trajectory is best modeled by brand share decline plus gross-to-net compression. Unit growth is uncommon in mature generic markets unless the brand regains preferred access or a patient subgroup is effectively “locked in” due to RDT administration need.

Scenario mapping

• Bull case: RDT-specific coverage or preferred tier retention maintains modest share; rebates stabilize.
• Base case: continuing generic substitution reduces share; net sales flatten then decline modestly.
• Bear case: re-tiering to nonpreferred or deeper PBM-driven substitution triggers accelerated share loss and margin pressure.

Key Takeaways

• KLONOPIN RAPIDLY DISINTEGRATING is exposed to generic clonazepam substitution and benzodiazepine category contracting controls.
• Demand is driven more by payer access and PBM formulary position than by clinical differentiation, since the active ingredient is mature and substitutable.
• Financial trajectory in mature branded benzodiazepines usually follows declining brand share with stabilization at a lower net sales base, with quarter-to-quarter volatility from channel and inventory cycles for RDT formats.
• The main commercial risks are formulary tier downgrades, rebate-driven margin compression, and substitution pathways that reduce RDT-specific advantage.

FAQs

1. Why do benzodiazepine RDT brands lose share faster than some other specialty formulations?
2. How do PBM copay and prior authorization policies typically affect clonazepam brand fills?
3. What patient factors increase the chance an RDT brand retains demand after generic entry?
4. How do wholesale inventory corrections impact reported net sales for mature, generic-exposed brands?
5. What contracting strategies are most effective to defend branded share in generic-saturated clonazepam markets?

References

1. (No sources were provided in the prompt; no reliable, citable financial/market-dynamics dataset can be listed.)